Lead Product(s) : PL-14
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyrizon Reports PL-14 Allergy Blocker Safe in Human Nasal Tissue Model
Details : PL 14 is an intranasal hydrogel allergy blocker being developed by Polyrizon using its platform technology for the treatment of allergy.
Product Name : PL-14
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 25, 2025
Lead Product(s) : PL-14
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PL-14
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Eurofins CDMO
Deal Size : Undisclosed
Deal Type : Agreement
Polyrizon Enters GMP Manufacturing Agreement for PL-14 Allergy Blocker Trial
Details : The collaboration will supply Clinical Trial Material for Polyrizon’s PL-14 allergy blocker, in preparation for a clinical trial.
Product Name : PL-14
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 02, 2024
Lead Product(s) : PL-14
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Eurofins CDMO
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : VB-601
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VB-601 is the Company’s lead anti-MOSPD2 antibody for immune-inflammatory indications, for which a briefing package for the pre-IND meeting was submitted in June. Based on the FDA's feedback, VBL plans to advance its IND-enabling activities for VB-601 ...
Product Name : VB-601
Product Type : Antibody
Upfront Cash : Inapplicable
August 09, 2020
Lead Product(s) : VB-601
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amilo-5MER
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Hebrew University Of Jerusalem
Deal Size : Inapplicable
Deal Type : Inapplicable
Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program
Details : The 5 amino acids sequence of Amilo-5MER is homologue to a specific MTADV sequence in the human CD44 variant found in synovial fluid cells from joints of rheumatoid arthritis (RA) patients.
Product Name : Amilo-5MER
Product Type : Peptide
Upfront Cash : Inapplicable
June 08, 2020
Lead Product(s) : Amilo-5MER
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Hebrew University Of Jerusalem
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ApoGraft Treated Stem Cell
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Details : Cellect Biotechnology has signed a development agreement with an international consortium to examine the therapeutic effects of ApoGraft treated stem cells on the reduction of pulmonary manifestations caused by COVID-19.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 21, 2020
Lead Product(s) : ApoGraft Treated Stem Cell
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Allocetra
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Upon issuance, the new patent will provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases comprising gout, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.
Product Name : Allocetra
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 11, 2020
Lead Product(s) : Allocetra
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VB-601
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New data implicating the potential of VBL's proprietary anti-MOSPD2 antibodies for treatment of rheumatoid arthritis (RA) is being presented today at the European League Against Rheumatism (EULAR) 2020 E-Congress.
Product Name : VB-601
Product Type : Antibody
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : VB-601
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable